In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device BioPharmaceutical Commercial

Snapshot: July Highlights

  • Data

Executive Summary

A selection of articles you might have missed from July 2022, including an exploration of this year's top selling drugs, an in depth discussion about how life sciences leadership is changing, as well as a look into AC Immune's Parkinson's research.

You may also be interested in...



Execs On The Move: January 2023

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.  

AI Medical Technology Doubles Down On Melanoma With Trials And Financing

Over the past month, the company has released positive clinical trial results and raised more cash, both of which will help on its way to combat melanoma.

Execs On The Move, January 2023: Spun-Off GE Healthcare Names Board, Officers

An interactive view of medtech executive changes from the month of January 2023, including GE Healthcare's new leadership as a standalone company.

Table

View full table

Topics

Tags:
Medical Device BioPharmaceutical Commercial
Latest Headlines

Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles

Instead Of VC, Try Philanthropy: Inside Medical Research Charity LifeArc

Execs On The Move: January 2023

Financing Quarterly Statistics, Q4 2022

See All
UsernamePublicRestriction

Register

IV146653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By